Literature DB >> 12151533

Overexpression of HGF retards disease progression and prolongs life span in a transgenic mouse model of ALS.

Woong Sun1, Hiroshi Funakoshi, Toshikazu Nakamura.   

Abstract

Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disease characterized by a progressive loss of motoneurons and degeneration of motor axons. We show that overexpression of hepatocyte growth factor (HGF) in the nervous system attenuates motoneuron death and axonal degeneration and prolongs the life span of transgenic mice overexpressing mutated Cu2+/Zn2+ superoxide dismutase 1. HGF prevented induction of caspase-1 and inducible nitric oxide synthase (iNOS) in motoneurons and retained the levels of the glial-specific glutamate transporter (excitatory amino acid transporter 2/glutamate transporter 1) in reactive astrocytes. We propose that HGF may be the first example of an endogenous growth factor that can alleviate the symptoms of ALS by direct neurotrophic activities on motoneurons and indirect activities on glial cells, presumably favoring a reduction in glutamatergic neurotoxicity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12151533      PMCID: PMC6758174          DOI: 20026634

Source DB:  PubMed          Journal:  J Neurosci        ISSN: 0270-6474            Impact factor:   6.167


  44 in total

1.  Hepatocyte growth factor inhibits CNS autoimmunity by inducing tolerogenic dendritic cells and CD25+Foxp3+ regulatory T cells.

Authors:  Mahdia Benkhoucha; Marie-Laure Santiago-Raber; Gregory Schneiter; Michel Chofflon; Hiroshi Funakoshi; Toshikazu Nakamura; Patrice H Lalive
Journal:  Proc Natl Acad Sci U S A       Date:  2010-03-23       Impact factor: 11.205

Review 2.  Motor neuron trophic factors: therapeutic use in ALS?

Authors:  Thomas W Gould; Ronald W Oppenheim
Journal:  Brain Res Rev       Date:  2010-10-21

3.  Biological roles of hepatocyte growth factor-Met signaling from genetically modified animals.

Authors:  Takashi Kato
Journal:  Biomed Rep       Date:  2017-10-18

4.  ITIH4 and Gpx3 are potential biomarkers for amyotrophic lateral sclerosis.

Authors:  Hirotaka Tanaka; Masamitsu Shimazawa; Masafumi Takata; Hideo Kaneko; Kazuhiro Tsuruma; Tsunehiko Ikeda; Hitoshi Warita; Masashi Aoki; Mitsunori Yamada; Hitoshi Takahashi; Isao Hozumi; Hiroshi Minatsu; Takashi Inuzuka; Hideaki Hara
Journal:  J Neurol       Date:  2013-02-23       Impact factor: 4.849

5.  Sensory involvement in the SOD1-G93A mouse model of amyotrophic lateral sclerosis.

Authors:  Yan Su Guo; Dong Xia Wu; Hong Ran Wu; Shu Yu Wu; Cheng Yang; Bin Li; Hui Bu; Yue Sheng Zhang; Chun Yan Li
Journal:  Exp Mol Med       Date:  2009-03-31       Impact factor: 8.718

6.  Stem cell factor-activated bone marrow ameliorates amyotrophic lateral sclerosis by promoting protective microglial migration.

Authors:  Tomoya Terashima; Hideto Kojima; Hiroshi Urabe; Isamu Yamakawa; Nobuhiro Ogawa; Hiromichi Kawai; Lawrence Chan; Hiroshi Maegawa
Journal:  J Neurosci Res       Date:  2014-07       Impact factor: 4.164

7.  Neurotrophic growth factors for the treatment of amyotrophic lateral sclerosis: where do we stand?

Authors:  Alexandre Henriques; Claudia Pitzer; Armin Schneider
Journal:  Front Neurosci       Date:  2010-06-11       Impact factor: 4.677

8.  Decreased Serum Hepatocyte Growth Factor (HGF) in Individuals with Depression Correlates with Severity of Disease.

Authors:  A J Russo
Journal:  Biomark Insights       Date:  2010-08-03

Review 9.  MET receptor tyrosine kinase as an autism genetic risk factor.

Authors:  Yun Peng; Matthew Huentelman; Christopher Smith; Shenfeng Qiu
Journal:  Int Rev Neurobiol       Date:  2013       Impact factor: 3.230

10.  Current and emerging treatments for amyotrophic lateral sclerosis.

Authors:  Stefano Zoccolella; Andrea Santamato; Paolo Lamberti
Journal:  Neuropsychiatr Dis Treat       Date:  2009-11-16       Impact factor: 2.570

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.